4/A: CorMedix CLO Amends Filing on Tax Withholding
Amendment to Insider Transaction Report
CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, filed an amended Form 4 to correct an omission regarding shares withheld for tax liability.
Summary
- An amendment to a previously filed Form 4 was submitted by Beth Zelnick Kaufman, Chief Legal Officer of CorMedix Inc.
- The amendment clarifies that the Issuer withheld 8,880 shares of common stock on August 29, 2025.
- These shares, valued at $14.83 each, were withheld to satisfy the Reporting Person's tax liability obligation.
- Following this transaction, Beth Zelnick Kaufman beneficially owns 180,418 shares of CorMedix Inc. common stock.
- The original Form 4, filed on September 3, 2025, had omitted this specific detail.
Sentiment
Score: 5
Explanation: The filing is an administrative correction of a routine transaction (tax withholding), which has no material impact on the company's operations or financial health.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- The Issuer withheld 8,880 shares of common stock from Beth Zelnick Kaufman, the Chief Legal Officer, to cover her tax liabilities, which constitutes a related party transaction.
Stakeholder Impact
- Shareholders: Minimal to no direct impact, as it's a routine administrative correction of an insider transaction.
- Regulatory Bodies: The amendment demonstrates compliance with SEC reporting requirements by correcting an omission.
Key Dates
| Date | Description |
|---|---|
| 08/29/2025 | Date of the transaction where 8,880 shares were withheld for tax liability. |
| 09/03/2025 | Date the original Form 4 was filed, which omitted the tax withholding detail. |
| 09/08/2025 | Date the amended Form 4/A was filed to correct the omission. |
Recommendation
holdThis filing is an administrative amendment to correct a routine insider transaction (tax withholding). It provides no new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The correction itself is a positive for regulatory compliance but does not impact the fundamental investment thesis.
Keywords
CorMedix, CRMD, SEC Form 4/A, insider transaction, beneficial ownership, tax withholding, Beth Zelnick Kaufman, Chief Legal Officer, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.